AHR Antibody [FITC]

Aryl hydrocarbon Receptor (AhR) is a ligand-activated transcriptional activator that binds to XRE promoter region of its target genes and has been established to activate phase I/II xenobiotic biotransformation enzyme genes. AhR binds MYBBP1A and its efficient DNA binding requires dimerization with another bHLH proteinsuch as ARNT. Besides interacting with NEDD8 and IVNS1ABP, AhR also interacts with coactivators including SRC-1, RIP140 and NOCA7, and with the corepressor SMRT. AhR localize to cytoplasm and upon binding with ligand followed by interaction with a HSP90, it translocates to the nucleus. AhR has been shown to be induced or repressed by TGFB1 as well as dioxin in a cell-type specific fashion, whereas cAMP, retinoic acid, TPA (12-O-tetradecanoyl phorbol-13 acetate) have been shown to exert repressive effects on AhR. As a member of bHLH-PAS (basic helix-loop-helix Per/ARNT/Sim) family, AhR has been implicated in physiological processes such as circadian cycle, neurogenesis, organs development and regulation of cell-cycle as well as the alternative signaling pathways (independently of exposure to xenobiotics). AhR-null mice exhibit infertility, liver abnormalities and cardiovascular problems such as a defective closure of the ductus venosus, indicative of the implication of the AhR in various developmental processes.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array NB100-2289F

• AHR Antibodies
• AHR ELISA Kits
• AHR Lysate
• AHR Proteins